OncoMatch/Clinical Trials/NCT07040969
Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors
Is NCT07040969 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Spray of spirulina derivatives for radiation-induced oral mucositis.
Treatment: Spray of spirulina derivatives — To evaluate the efficacy and safety of Spirulina-Derived Product for prevention and treatment of oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors.
Check if I qualifyExtracted eligibility criteria
Disease stage
Excluded: Stage IV
non-metastatic head and neck malignant tumors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify